Prognostic value of vascular endothelia growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis
Cancer Epidemiology, Biomarkers & Prevention, 05/09/2012
Chen M et al. – In this meta-analysis, elevated VEGF expression was associated with poor survival in patients with esophageal cancer, but not esophageal sdenocarcinoma. Impact:These results support further investigation of VEGF expression for predicting poor survival in patients with esophageal carcinoma, and may have implications for treatments directed at inhibiting VEGF-mediated angiogenesis.
Searches were applied to PubMed and EMBASE until December 31, 2011, without language restrictions.
Studies were assessed for quality using REMARK (Reporting recommendations for tumor MARKer prognostic studies).
Data were collected comparing overall survival in patients with high VEGF level as compared to those with low level.
We conducted a systematic review of 31 studies (n=2387 patients) and completed a meta-analysis of 30 studies (n=2345 patients) that correlated VEGF levels with overall survival.
Data were synthesized with hazard ratios.
The estimated risk of death was 1.82-fold greater in patients with high VEGF expression (95% confidence interval, 1.58-2.08).
The heterogeneity was not significant (P=0.130) between studies. High VEGF expression was associated with worse survival in esophageal squamous cell carcinoma (hazard ratio, 1.81; 95% confidence interval, 1.57-2.10) and there was no significance in between-study heterogeneity (P=0.185).
Data collected were not sufficient to determine the prognostic value of VEGF in patients with esophageal adenocarcinoma.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.